Lung Cancer
Conditions
Keywords
lung, cancer, quality of life
Brief summary
This study will investigate the effectiveness of using the European Organisation for Research and Treatment of cancer Core Quality of Life Questionnaire (EORTC QLQ-C30 + LC 13) to identify and target therapies in patients with lung cancer. The study will assess whether using the questionnaire will result in an improvement in QoL.
Detailed description
Patients with lung cancer who have completed a course of treatment (or who are in-between treatment) at the Royal Marsden Hospital would be eligible for inclusion in the study. Participants will be randomised into 3 groups. Group 1 - this group will complete the QoL questionnaire and will receive targeted therapies by a doctor (and other members of the oncology team) during a clinic consultation. Group 2 - will complete the QoL questionnaire however the questionnaire will not be seen by the doctor during a clinic consultation. Group 3 - the control group will not complete the QoL questionnaire before a clinic consultation. All patients will complete a diary of all contact they have with health care professionals during the study. The study will last for 6 weeks and at the end of the study all patients will complete the QoL questionnaire.
Interventions
OTHERIntervention
OTHERAttention
OTHERControl
Sponsors
Royal Marsden NHS Foundation Trust
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* male or female age \> 18 years * patients who are able to adequately understand written and spoken english * diagnosis of lung cancer (non small cell, small cell, mesothelioma) * no plan to commence treatment (chemotheraphy, targeted therapies, radioterhapy, surgery) with 6 weeks * both radically or palliatively treated patients remain eligible * patients whose toxicities from their primary treatment has resolved or have stabilised for a period of 7 days
Exclusion criteria
* patients are taking part on any other QoL studies * taking part in any other studies that requires QoL questionnaires, extra visits or investigations * currently on treatment (chemotherapy, radiotherapy, surgery or targeted therapies) * they have on going toxicities from their treatment which have not been stablised (required intervention within last 7 days)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate whether the use of QOL questionnaires during the assessment and management of lung cancer patients results in improved quality of life | — |
Secondary
| Measure | Time frame |
|---|---|
| To investigate whether the use of EORTC QLQ-C30 + lung cancer module results in less patient contact with health care professionals during the 6 week study period for the 3 groups | — |
Countries
United Kingdom
Contacts
Primary ContactDr M O'Brien
Backup ContactMr M Laybourne
Outcome results
None listed